Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

89 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Current reports have demonstrated that copeptin predicts disease progression and prognosis in cirrhotic patients, independent of liver-specific scoring systems. To the best of our knowledge, few studies have addressed the association between copeptin and sepsis in cirrhotic patients, however, they were performed on different types of infections. Therefore, we will conduct this study with a focus on it is possible role in patients with SBP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelets to Lymphocytes Ratio and Monocytes to Lymphocytes Ratio as Predictors of Response to Treatment in Cirrhotic Patients With Spontaneous Bacterial Peritonitis.

NCT05850858

Cirrhotic Patients With Spontaneous Bacterial Peritonitis

UNKNOWN

Risk Factors of Spontaneous Fungal Peritonitis in Cirrhotic Patients

NCT05117073

Spontanous Fungal Peritonitis

COMPLETED

Platelet Indices Could Predict Spontaneous Bacterial Peritonitis in Cirrhotic Ascitic Patients

NCT03172013

Cirrhosis, Liver

UNKNOWN

Prediction of SBP in Cirrhotic Patients by Platlet Count, Na and AlBl Index.

NCT07116369

Spontaneous Bacterial Peritonitis

NOT_YET_RECRUITING

Clinical Value of the Developed Scoring Systems for Predicting Spontaneous Bacterial Peritonitis in Cirrhotic Ascites

NCT06402071

Cirrhotic Ascitic Patients

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spontaneous Bacterial Peritonitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ascites without SBP

Cirrhotic ascitic patients not diagnosed with SBP

Serum copeptin

Intervention Type DIAGNOSTIC_TEST

Blood test

Ascites with SBP

Cirrhotic ascitic patients diagnosed with SBP

Serum copeptin

Intervention Type DIAGNOSTIC_TEST

Blood test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum copeptin

Blood test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The diagnosis of liver cirrhosis will be based on clinical data and findings on abdominal ultrasound. The diagnosis of SBP will be based on the presence of at least 250 cells/ml PMNLs in the ascitic fluid, with or without positive ascitic fluid culture in the absence of hemorrhagic ascites and secondary peritonitis

Exclusion Criteria

* Patients with heart failure, coronary insufficiency, advanced chronic respiratory disease, polyuria-polydipsia syndrome and hypotension or shock.

* Patients with chronic kidney disease treated with hemodialysis before admission.
* Patients with previous liver or kidney transplantation.
* Patients with intraabdominal malignancy.
* Patients with severe infection other than SBP.
* Patients who had received antibiotics before hospital admission.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No